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Abstract 
The (+)strand RNA viruses include a very large group of viruses that cause 
epidemic diseases in humans, including dengue fever and gastroenteritis. 
The human (+)RNA viruses include Flaviviruses  (FV) and Norovirus (NV). 
Both encode for proteins essential for viral replication, such as the RNA 
dependent RNA polymerase (RdRp). Since human cells lack RdRp, it 
appears as one of the most promising targets for antivirals development. I 
worked on the identification of new non-nucleotide inhibitors against FV 
and NV, using RdRp as the main target. In this context, suramin and NF023 
have been identified in my lab as NV RdRp inhibitors that, however both are 
hampered in their application by pharmacokinetics problems. To overcome 
such problems, I analyzed the potential inhibitory role of Naf2, a fragment 
derived from these two molecules. Although Naf2 showed a low inhibitory 
activity, the crystal structures of NV RdRp/Naf2 complex revealed a new 
binding site. To further map this new site, I tested a Naf2 related molecule, 
PPNDS. The crystal structures of the RdRp/PPNDS complex revealed 
interesting features about the new binding site. I also focused on structurally 
related molecules synthesized following structure-driven information. NV 
RdRp crystal structures in complex with one of these compounds (Cpd6) 
were analyzed, providing new knowledge on the interactions between a 
small fragment and NV RdRps, establishing a platform for structure-guided 
drug optimization. In parallel to the NV work, I screened in silico a library 
of compounds against FV RdRp. One of the best compounds identified 
(HeE1-2Tyr) was able to inhibit the RdRp activity and several FVs in cell-
based assays. Although the crystallographic analyses don't reveal clear 
enough electron density for the inhibitor, indirect evidence suggests that 
HeE1-2Tyr interferes with the RdRp priming loop that appears disordered. 
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1. State of the Art 
 
1.1 General introduction about viruses 
 Viruses are subcellular infectious agents that are obligate 
intracellular parasites. They infect and take over a host cell in order to 
replicate.  
 The mature extracellular virus particle is called virion. The virion 
contains a DNA or RNA genome wrapped in a protein coat called capsid or 
nucleocapsid. Some viruses display a lipid envelope surrounding the 
nucleocapsid. The capsid and the envelope play many roles, including virus 
attachment to cells, entry into cells, release of the capsid contents into the 
cells, and packaging of newly formed viral particles. The capsid and 
envelope are also responsible for transfer of the viral genetic material from 
one cell to another.  
Three broad classes of viruses can be recognized which may have 
independent evolutionary origins (Table 1):  
1) the first class hosts a genome based on DNA, either single stranded or 
double stranded, and the genome is replicated by direct DNAàDNA 
copying. During infection, the viral DNA is transcribed by cellular and/or 
viral RNA polymerases to produce mRNAs for translation into viral 
proteins. Replication of the genomes of most eukaryotic DNA viruses and 
assembly of progeny viruses occur in the nucleus; 
2) the second class of viruses contains an RNA genome, and the RNA is 
replicated by direct RNAàRNA copying. Some RNA viruses host a 
genome that is already the messenger RNA; these are defined as plus-
stranded RNA viruses. Other RNA viruses have a genome that is anti-
messenger sense, defined as minus strand RNA viruses. In the case of the 
RdRp targeting antivirals 
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minus-strand RNA viruses and double-strand RNA viruses, the RNA 
synthesizing enzymes also synthesize mRNA, and are packaged in the 
virion, because their genomes cannot function as mRNA. Replication of the 
genome proceeds through RNA intermediates that are complementary to the 
genome in a process that follows the same rules as DNA replication; 
3) the third class of viruses encodes the enzyme reverse transcriptase, and 
these viruses have an RNAà DNA retro-transcription step in their life 
cycle. The genetic information encoded by these viruses thus alternates 
between being encoded in RNA and in DNA. 
With the exception of the retroviruses, which are diploid (they 
contain two identical copies of the single-stranded genomic RNA), all the 
viruses are haploid (they contain only one copy of the genomic nucleic acid).  
Viruses are classified into species on the basis of a close relationship. 
Virus species that exhibit close relationship are then grouped into a genus. 
Species within a genus usually share significant nucleotide sequence 
identity. Genera are grouped into families, which can be considered the 
fundamental unit of virus taxonomy. Classification into families is based on 
the type and size of the nucleic acid genome, the structure of the virion and 
the strategy of replication used by the virus.  
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 Nucleic acid Genome size (kbp) Segments Family 
CLASS 1 
DS DNA 
130-375 1 Poxviridae 
170-190 1 Asfariviridae 
170-400 1 Iridoviridae 
120-220 1 Herpesviridae 
90-230 1 Baculoviridae 
36-48 1 Adenoviridae 
5 1 Polyomaviridae 
6.8-8.4 1 Papillomaviridae 
Varia 1 Several families 
SS DNA 6-8 1 Parvoviridae Varia 1 Several families 
CLASS 2 
DS RNA 
20-30 10-12 Reoviridae 
5.9 2 Birnaviridae 
4.6-7.0 1 o 2 Three families 
SS (+) RNA 
28-33 1 Coronaviridae 
13-16 1 Arteriviridae 
10-13 1 Togaviridae 
10-12 1 Flaviviridae 
7-8.5 1 Picornaviridae 
7-8 1 Astroviridae 
8 1 Caliciviridae 
Varia 1 Many families 
SS (-) RNA 
15-16 1 Paramyxoviridae 
13 1 Filoviridae 
13-16 1 Rhabdoviridae 
9 1 Bornaviridae 
13 8 Orthomyxoviridae 
12-23 3 Bunyaviridae 
11 2 Arenaviridae 
CLASS 3 
SS RNA RT 7-10 dimer Retroviridae 
DS RNA RT 3 1 Hepadnaviridae 8 1 Caulimoviridae 
Table 1. Classification of the viruses based on the nucleic acid. The size, the structure of the 
virion and the main families are indicated. 
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1.2 The Caliciviridae Family 
The Caliciviruses are non-enveloped viruses with icosahedral 
symmetry and diameter of about 30 nm. Caliciviruses are currently classified 
into 5 genera: Vesivirus, Lagovirus, Nebovirus, Sapovirus and Norovirus, 
two of which, the Norovirus and the Sapovirus, contain agents that cause 
human gastroenteritis. The Norovirus genus is subdivided into at least 5 
genogroups (GI-GV). Genogroups GI, GII and GIV infect humans and cause 
acute gastroenteritis. Futhermore, Noroviruses have been isolated from 
numerous other species including pigs (GII), cattle and sheeps (GIII) and 
mice (GV) (Figure 1). 
 
 
Fig 1. Subdivision of the Calicivirus family.  
 
 Calicivirus ancestor 
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The human Caliciviruses have been difficult to study so far; as a 
consequence, our knowledge is still limited. What we know of the molecular 
biology of Caliciviruses comes from studies of the non-human viruses. The 
murine Norovirus (mNV) is closely related genetically to the human 
Norovirus (hNV), thus providing an excellent model that will accelerate 
research on the mechanisms by which the Norovirus genome is expressed, 
and on the functions of the encoded proteins. 
The Norovirus genome is a compact single stranded positive sense 
RNA molecule of about 7.7 kb. The 5’ end of the genomic RNA is 
covalently attached to a virus encoded protein known as VPg, while the 3’ 
end is polyadenylated.  
The Norovirus genome is organised into three conserved open 
reading frames (ORFs, Figure 2a), with the exception of mNV, which has a 
fourth alternative ORF (Figure 2b). The fourth ORF is unique to the mNV 
cluster in GV, and has not yet been identified in any other Norovirus. The 
only member of the Caliciviridae family known to have an equivalent fourth 
ORF is human Sapovirus [1]; [2].  
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Fig 2. Organization of the hNV and mNV genomes. (a) The hNV genome is covalently 
attached to VPg (NS5) with a poly(A) tail, and is divided into three ORFs, common to all 
Noroviruses. ORF1 is translated as a polyprotein, which is cleaved by the viral protease 
NS6 to produce the NS proteins. ORF2 and ORF3 are translated from a subgenomic RNA. 
(b) mNV shares a similar genome organization, but has an additional alternative fourth 
ORF. ORF4 overlaps with ORF2 and is also translated primarily from the subgenomic RNA 
into the virulence factor 1 (VF1) protein. 
 
For all Noroviruses, ORF1 is translated as a large polyprotein, which 
is co- and post-translationally cleaved by the virus-encoded protease (mNV 
NS6/ hNV Pro) to release at least six mature non-structural (NS) proteins 
including NS6/Pro [3]. The other NS proteins include the viral RNA 
dependent RNA polymerase (mNV NS7/hNV Pol), mNV NS5/hNV VPg, 
the mNV NS3/hNV NTPase, mNV NS1/2/hNV p48, and NS4/hNV p22, 
which have both been implicated in formation of the replication complex 
[4]; [5].  
ORF2 and ORF3 are translated from a subgenomic RNA and encode 
the major and minor capsid proteins, VP1 and VP2 respectively. ORF4 of 
RdRp targeting antivirals 
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mNV is translated from an alternative reading frame within ORF2 and 
encodes the recently identified protein virulence factor 1 (VF1), a 
mitochondrially localised novel innate immune regulator [2]. 
The nomenclature for the Norovirus proteins is summarised in Table 
2. 
Protein name  
mNV hNV Functions 
NS1/2 p48 It may has a role in replication complex formation; contributes to persistence in mNV infections. 
NS3 NTPase RNA helicase; NTPase. 
NS4 p22 It may has a role in replication complex formation. 
NS5 VPg Genome linked protein involved in translation and replication. 
NS6 Pro Protease 
NS7 Pol RNA dependent RNA polymerase 
VP1 VP1 Major capsid protein 
VP2 VP2 Minor capsid protein 
VF1 - Virulence factor 
Table 2.  Nomenclature for the hNV and mNV proteins and their functions.  
 
Interaction of Noroviruses with the cell surface is known to involve 
carbohydrate structures, which in the case of hNV include the histo blood 
group antigens (HBGAs). Receptor binding and/or entry processes appear to 
be the limiting factors for hNV culture in immortalised cells, as viral RNA 
transfected into cells is able to undergo limited replication. 
Once a Norovirus VPg-linked RNA genome is released into the 
cytoplasm of a cell, it behaves as an mRNA template for the ‘pioneer round’ 
of viral RNA translation (Figure 3). For this to occur, the viral RNA is 
recognised by cellular translation initiation factors and is translated into 
protein by the cellular translational apparatus [6]. Translation of all 
Calicivirus genomes occurs by a novel mechanism involving VPg that is not 
RdRp targeting antivirals 
 11 
found in many other animal RNA viruses [7]. VPg covalently attached to the 
5’ end of the genome mediates translation of viral RNA, acting as a cap-
substitute and recruits host cell translation initiation factors. The extremities 
of Calicivirus genomes contain evolutionarily conserved RNA structures 
that are known to interact with host cell factors to promote viral replication 
and translation [8]; [9]. As many of the host factors form direct protein-
protein interactions with each other, it is possible that numerous cellular 
RNA-binding proteins contribute to the circularisation of the viral genome 
during translation and/or replication. It is possible that these types of RNA-
protein interactions play both positive and negative regulatory roles in the 
life cycle of Noroviruses. Translation of the ORF1 polyprotein is followed 
by co- and post-translational processing by the viral NS6 protease, and 
results in the release of the viral non-structural proteins ready for replication 
complex formation, and of their precursors, some of which are thought to be 
functionally active in replication [10]. Similarly to other positive strand 
RNA viruses, Norovirus replication occurs in close association with host-
derived membrane complexes in the cytoplasm [11]; [12]. The NS proteins, 
as well as the major and minor capsid proteins, co-localise with NS7 and 
dsRNA at this location, forming the replication complex [4]; [13]. Genome 
replication occurs via a negative sense RNA intermediate, and is carried 
over by the viral RdRp. The Norovirus RdRps, generally referred to as NS7, 
contain active site residues conserved among other positive strand RNA 
virus RdRps, and are structurally and functionally conserved [14]. The 
replicative properties of the mNV RdRp (NS7) are comparable in vitro to 
those of the hNV RdRp, supporting the use of mNV for replication studies 
[15]. The process of initiation of negative sense RNA synthesis on the 
incoming parental viral RNA is not fully understood but the Norovirus RdRp 
RdRp targeting antivirals 
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has two mechanisms of initiation that have been demonstrated both in vitro 
and in cells: de novo, and VPg-dependent [16]. Following the generation of 
a double-stranded RNA, the synthesis of positive sense genomic and 
subgenomic RNA occurs.  
The processes behind viral assembly, encapsidation and the exit of 
noroviruses are largely unknown. The ability of VP1 to self-assemble into 
virus-like particle (VLPs) morphologically and antigenically 
indistinguishable from native virions suggests that it may be sufficient to 
drive capsid assembly during virus replication [17], although the 
involvement of cellular proteins cannot be excluded. 
RdRp targeting antivirals 
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Fig 3. Outline of the Norovirus lifecycle. hNV and mNV are thought to attach to the cell 
surface (1) using various carbohydrate attachment factors. This is not sufficient to mediate 
entry, therefore binding to an unidentified protein receptor is thought to be required (2). 
Entry (3) and uncoating (4) proceed through yet undefined pathways. The incoming viral 
genome is translated (5), through interactions with VPg at the 5’ end of the genome (red 
traingle) and the cellular translation machinery. The ORF1 polyprotein is co- and post-
translationally cleaved (6) by the viral protease NS6. The replication complex (7) is formed 
by recruitment of cellular membranes to the perinuclear region of the cell (not shown), 
through interactions in part with NS1/2 and NS4. Genome replication (8) occurs via a 
negative strand intermediate, and genomic and subgenomic RNA are generated by the viral 
RdRp/NS7, using both de novo and VPg-dependent mechanisms of RNA synthesis. The 
replicated genomes are translated (within the replication complex) or packaged into the 
capsid, VP1, for virion assembly (9), which move through the exit (10). 
RdRp targeting antivirals 
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1.3 Norovirus RdRp 
The overall structure of NV RdRp can be described using an analogy 
to a right hand, as commonly referred to for a wide range of nucleic acid 
polymerases (Figure 4). The active site consists of G342D343D344 residues 
belonging to the palm subdomain. The incoming NTP enters between finger 
and palm domains (close to the active site) and the dsRNA exits channel is 
near the palm and thumb domains. 
Fig 4. NV RdRp overall structure. Ribbon diagram showing front (A) and top (B) views of 
NV RdRp. The amino-terminal region is red, fingers subdomain magenta, palm subdomain 
green and cyan, thumb subdomain blue, and C-terminal region yellow. The N- and C- 
termini are marked. 
 
In addition to the fingers, palm, and thumb subdomains common to 
all polymerases, NV RdRp has an additional N-terminal domain bridging the 
fingers and thumb subdomains, common to all Caliciviruses RdRps of 
known three-dimensional structure [18].  
A particular feature is a region of hydrophobic residues built by 
Trp29, Pro421, Met430, and Ile431, fairly well conserved in Noroviruses, 
but poorly conserved in other Caliciviruses. Although the functional 
importance of the resulting NV RdRp dimers is not clear, the location of this 
hydrophobic patch near the top of the active site cleft suggests that protein-
RdRp targeting antivirals 
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protein interactions important for RNA binding or RNA synthesis may be 
mediated by this contact surface.  
A particularly striking feature of the NV RdRp structures is the 
location of the C-terminal segment in the active site cleft near the two 
catalytic Asp residues (Asp343 and Asp 344). This segment interacts mainly 
with the wall of the active site cleft formed by the thumb domain, is well 
exposed to solvent, and likely is characterized by conformational flexibility 
(Figure 5).  
Fig 5. Carboxy-terminal segment of NV RdRp. LIGPLOT diagram of hydrogen bonding 
(dashed green lines) and van der Waals interactions between residues 501–507 and other 
residues in the polymerase. 
 
The structural similarities shared among NV, HCV, and 
bacteriophage φ6 RdRps suggest that the C-terminal segment in NV RdRp 
may also play a role in initiating RNA replication.  
The location of the C-terminal sequence in the NV RdRp active site 
appears to block the entry of an RNA primer-template duplex. The presence 
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of the C-terminal segment primarily interferes with the entry of the primer 
strand of an RNA duplex into the active site cleft, but it is well positioned to 
interact with short di- or tri-nucleotide primers, or possibly with hairpin 
structures forming near the active site. 
An alignment of the C-terminal sequences from Norovirus RdRp 
reveals a high degree of sequence conservation in this region, indicating that 
a similar structure is found in both genogroups of Noroviruses. A lower 
degree of sequence similarity in this region of RdRps from other Calicivirus 
genera, as well as the lack of structural similarity between the last 25 
residues of the NV and RHDV RdRps, suggests that the structure of the C-
terminus differs in polymerases from these viruses. mNV and hNV RdRp 
sequence alignment showed a residue identity of 59.0 %. In a comparative 
analysis of 3D structural similarities between RdRps of different members of 
the Caliciviridae family, the apo structures of mNV and hNV RdRp proteins 
[14]; [19] were found to be well superimposed in the N- terminal extension 
and the fingers domain. Significant structural variation was instead found in 
the thumb and palm subdomains containing the C-terminal and the loop 
regions (residues 302–307, 374–381 and 471–480) (Figure 6). The loop I is 
close to the active site, the loop II is adiacent to the predicted rNTP-binding 
site [19] and loop III is near to the dimer interface and the helix backbone.  
Structural comparison between mNV RdRp– and hNV RdRp–RNA 
complexes [20]; [21] revealed significant differences in the RNA-binding 
loop (residues 433–440), which suggests that RNA binding likely causes 
conformational changes in the mNV RdRp active site.  
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Fig 6. Variation between mNV and hNV RdRp structures. Variation in the loop regions 
corresponding to loops I (residues 302–307), II (374–381) and III (471–480) and the RNA-
binding loop (residue 433–440) are marked on the overall structure model in the centre, and 
close-ups are shown. mNV RdRp is shown in red, while hNV RdRp is shown in blue 
(2B43; strain Hu/NLV/Dresden174/1997/GE), green (1SH0; apo protein), yellow (3BSO; 
hNV RdRp in complex with dsRNA) and cyan (3H5X; hNV RdRp in complex with 
dsRNA) [22].  
 
RdRps, like other polynucleotide polymerases, follow a five-step 
reaction cycle involving (i) the binding of an NTP complementary to the 
base of the template to form an initial “open” complex, followed by (ii) a 
conformational change to the “closed” complex, (iii) nucleotidyl transfer and 
translocation, (iv) a second conformational change, and finally (v) the 
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release of pyrophosphate (Figure 7). 
To provide a more detailed structural basis for understanding the 
nucleotidyl transfer reaction in viral RdRps, the crystal structures of hNV 
RdRp in complex with oligonucleotide (5’-UGCCCGGG-3’), two Mn2+ 
ions, and either the natural substrate CTP or the nucleotide inhibitor NCT 
have been determined [20]. 
 These structures reveal for the first time details of ternary 
RdRp+RNA+NTP complexes trapped immediately prior to the nucleotidyl 
transfer reaction (the closed complex iii in Figure 7). 
 
Fig 7. General kinetic scheme for nucleotide incorporation in RdRps and other polymerases. 
E, RdRp enzyme; Rn, RNA oligonucleotide containing n nucleotides; Rn+1, RNA 
oligonucleotide containing n + 1 nucleotides; NTP, nucleoside triphosphate; PPi 
pyrophosphate. 
 
1.4 The Flaviviridae Family 
The family Flaviviridae belongs to the second class of viruses and 
consists of three genera: Pestivirus (i.e. bovine viral diarreha virus, BVDV), 
Hepacivirus (hepatitis C virus, HCV) and Flavivirus (i.e. Dengue virus, 
West Nile virus, Yellow Fever virus). 
 Flaviviruses are enveloped viruses [23] with single-stranded positive-
sense RNA genome of about 11 kb. Phylogenetic studies revealed that a 
common ancestor originated the presently known viruses, which 
schematically belong to three major evolutionary branches: tick-borne 
Flaviviruses (TBFVs), mosquito-borne Flaviviruses (MBFVs) and 
of the RdRP is nearly identical to the unbound form (9). This
observation, in combination with the modes of binding
observed for divalent metal cations and NTPs in the FMDV
complexes, further suggest that the NV RdRP!RNA!NTP com-
plex is a closed complex trapped immediately prior to catalysis,
whereas the FMDV complexes are open complexes trapped at
earlier or later steps of the reaction cycle.
Interactions betweenRdRP, RNA,NTPs, andMetal Ions at the
Active Site—The structures of the NV RdRP NCT and CTP
complexes provide the first high resolution views of RdRP com-
plexes trapped immediately before nucleotidyl transfer. Indi-
rect effects from crystal packing appear to have fortuitously
trapped these complexes at this stage of the reaction cycle. The
distal end of the primer-template duplex is located near a sym-
metry-related polymerase molecule, and there is insufficient
space for primer extension to occur in this crystal form. As a
result, polymerase molecules in this crystal form bind sub-
strates and assemble active complexes that can only proceed up
to the point immediately prior to nucleotidyl transfer.
The intricate network of interactions surrounding the bound
nucleotide reveals at high resolution several key elements
underlying substrate binding and catalysis in RdRPs (Fig. 3).
The NTP bases form hydrogen bonds with the complementary
guanosine base of the template and stack against the 3!-termi-
nal base of the primer, as well as the Arg-182 guanidino group
(Fig. 3). Arg-182 is highly conserved inRdRPs (Motif F3) (5) and
is near the NTP !-phosphate (3.5 Å). Arg residues occupy a
similar position in all viral RdRPswith known structures, aswell
as distantly related enzymes like HIV reverse transcriptase
(Table 2). The cytosine and nitrocytosine bases stack tightly
against Arg-182, unlike the looser interactions seen in themore
open FMDV complexes (9).
The interactions made by the ribose and triphosphate moi-
eties of the bound nucleotide indicate that the NV RdRP com-
plexes are perfectly positioned for nucleotidyl transfer (Fig. 3).
The 2!-OHaccepts a hydrogen bond fromAsn-309 anddonates
a hydrogen bond to Ser-300, which in turn donates a hydrogen
bond to Asp-247. This pattern of hydrogen bonding reveals
how these highly conserved residues (equivalent to poliovirus
RdRP residues 297, 288, and 238,
respectively) distinguish ribonucle-
otides from 2!-deoxyribonucleoti-
des (24–26). A similar network of
hydrogen bonds is seen in one of
the reovirus!NTP!RNA complexes
(8), but the more open FMDV
complexes or binary poliovirus
RdRP!NTP complexes do not form
the same hydrogen-bonding pat-
tern, suggesting that ribonucle-
otide selection occurs in the
closed complex formed immedi-
ately before catalysis (9, 27).
Two Mn2" ions also coordinate
to three highly conserved Asp resi-
dues and the NTP triphosphate
moiety to mediate catalysis through
the two-metal-ion mechanism (10,
28) (Fig. 3). Metal ion A octahedrally coordinates to the 3!-OH
nucleophile of the primer, the NTP !-phosphate, the carboxy-
late groups ofAsp-242,Asp-343, andAsp-344, aswell as awater
molecule. By donating hydrogen bonds to the negatively
charged primer phosphodiester and NTP !-phosphate groups,
thiswatermoleculemay be activated to become a better general
base catalyst (7), thus allowing it to abstract a proton from the
primer 3!-OH (2.8 Å away) following a mechanism similar to
that proposed for DNA polymerase " (29, 30). Metal ion B also
octahedrally coordinates to the side chain carboxylate groups of
Asp-242 and Asp-343, the main chain carbonyl group of Tyr-
243, as well as a single oxygen atom from each of the !, ", and #
phosphate groups of the NTP.
DISCUSSION
Trapping of a Preinsertion Conformation of NV RdRP via
Constraints from Crystal Packing—The recombinant form of
NV RdRP used in these studies is enzymatically active (11), and
there is surprisingly clear evidence of this activity in the crystal
structure itself. Because the primer-template oligonucleotide is
self-complementary and symmetrical, each oligonucleotide
duplex contains two 5!-overhangs where primer extension can
occur. In the NV RdRP!RNA!NTP complexes, the end of the
duplex found in the enzyme active site reveals the presence of a
3!-terminal guanosine residue in the primer and a 3!-GU-5!
sequence for the single-stranded 5!-overhang of the template
strand. CTP or NCT forms a Watson-Crick base pair with the
guanosine residueof the template, but crystal packing interactions
at the distal end of the primer-template duplex appear to impede
the translocation event following nucleotidyl transfer, thus trap-
ping this complex. Surprisingly, the end of the primer-template
duplex that is located distal from the active site reveals that either
a cytidine or 5-nitrocytidine residue has been added to the primer
strand, presumablyprior to crystallization.This residuemusthave
been added when this end of the duplex was bound at the active
site. Following the addition of this single residue, the duplexmust
have dissociated from the enzyme and bound in the opposite ori-
entation prior to crystallization.
FIGURE 1. A, general kinetic scheme for nucleotide incorporation in RdRPs and other polymerases (36, 37). E,
RdRP enzyme; Rn, RNA oligonucleotide containing n nucleotides; Rn"1, RNA oligonucleotide containing n" 1
nucleotides; NTP, nucleoside triphosphate; PPi pyrophosphate. B, stereoscopic view of the NV RdRP!ERnNTP
complex with the primer RNA strand colored yellow, template RNA strand inmagenta, fingers domain in blue,
palm domain in green, and thumb domain in red.
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Flaviviruses with no known vector (NKFVs, which are believed to be non-
vectorised viruses infecting bats and rodents) (Figure 8). 
 
Fig 8. Phylogenetic tree of the Flaviviruses based on NS3 polyprotein region, built using the 
neighbor-joining method [24].  
 
There are more than 80 different Flaviviruses [25] and most of them 
are important human pathogens, such as Yellow Fever virus (YFV), West 
Nile virus (WNV) and its Australian variant Kunjin virus (KUNV), Japanese 
encephalitis virus (JEV), Tick Born Encephalitis virus (TBEV), Saint Louis 
encephalitis virus (SLEV) and Dengue virus (DENV); the last one is 
continuing to spread and has emerged as a significant health threat 
throughout the world [26]. Flavivirus virions enter in the host cell by 
receptor mediated endocytosis. The viral mRNA has a cap I structure 
(7MeGpppA2'OMeC-RNA) lacking 3' poly(A) tail with an open reading frame 
(ORF) that is translated into a single polyprotein of about 3400 amino acids.  
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The viral polyprotein is processed by cleavage into 10 viral proteins, 
many of which are multifunctional and some membrane associated. 
Cleavage is effected by a combination of one or two viral encoded proteases 
and two or more cellular proteases. The viral proteins are classified into 
structural and non-structural (NS) proteins. The three structural proteins that 
form the virion framework are hosted at the 5' end of the RNA ORF. The 
remaining RNA codes for seven NS proteins involved in viral RNA 
replication and assembly. The structural proteins are identified as capsid (C; 
≈13 kDa), precursor membrane protein (PrM; ≈18 kDa), and envelope (E; 
≈54 kDa). The NS proteins are NS1 (≈39 kDa; [27]), NS2A (≈25 kDa; [28]), 
NS2B (≈14 kDa), NS3 (≈69 kDa), NS4A (≈16 kDa), NS4B (≈28 kDa; [29]), 
NS5 (≈104 kDa) [25]). The processing of the long polyprotein produced 
from the genome is complicated, and is presented in Figure 9 as an example 
of complex processing events that can occur in viral polyproteins associated 
with lipid bilayers. 
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Fig 9. Processing of the Flavivirus polyprotein into the structural and non-structural proteins 
of the virus. The structural proteins (blue) at the N-terminus of the polyprotein are 
processed primarily by signalase, with one late cleavage in prM due to furin. The non-
structural proteins (green) are mostly processed by the viral NS2B-NS3 protease. As 
indicated in the figure, the central 40 amino acids of NS2B interact with NS3, tying NS3 to 
the membrane; such interaction is essential for proteolytic function. The striped arrow 
shows the alternative site of cleavage within NS2A that may lead to an anchored form of 
NS1.  
 
The nucleocapsid protein is 5′ terminal in the genome and is removed 
from the precursor polyprotein by the viral NS2B-NS3 protease. Two 
envelope proteins, prM (precursor to M) and E (envelope), follow.  
NS proteins are cleaved in the following order: NS1, NS2A, NS2B, 
NS3, NS4A, NS4B and NS5. Their functions are summarised in Table 3: 
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Protein name Functions 
NS1 Required for RNA replication; other functions that are only poorly understood. 
NS2A Inhibits the production of interferon-α /β by infected cells; interacts with NS3 helicase domain. 
NS2B Required for the NS3 protease activity; 
NS3 Serine protease domain (Pro) at its N-terminal; helicase domain at its C-terminal. 
NS4A It may has a role in assembly of the viral replicase on intracellular membranes. 
NS4B It may has a role in assembly of the viral replicase on intracellular membranes. 
NS5 Methyltransferase domain at N-terminal; RdRp domain at C-terminal. 
Table 3. Nomenclature for Flavivirus proteins and their functions. 
 
Part of the NS proteins associate to form the viral replication 
complex and the new RNA synthesis co-localizes with NS1, NS2A, NS3, 
NS4A and NS5 ([30]; Figure 10).  
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Fig 10. Replication cycle of Flaviviruses. After recognition of the capped genome by 
cellular ribosomes, its translation produces a polyprotein comprising three structural and 
seven non-structural proteins. The non-structural proteins associate to form the viral 
replication complex, which is active in induced membrane structures called " vesicle 
packets " in the cytoplasm, as shown in DENV-2 and KUNV infected cells [30].   
 
 After the formation of the replication complex, negative-sense RNA 
is produced and used as a template for the synthesis of new positive-sense 
viral RNA, to be assembled into the newly produced viral particles.  
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1.5 Flavivirus RdRp 
With a molecular mass of about 100kDa, NS5 is the largest flaviviral 
protein; NS5 is also the most conserved protein across the genus. Early on, a 
motif of AdoMet-dependent MTases was identified within the N-terminal 
domain of NS5 [31], whereas RdRp motifs were identified in the NS5 C-
terminal domain [18,32-34]. 
As soon as the first polymerase structure became available [35], 
sequence comparisons allowed identification of a number of conserved 
motifs involved in catalysis, notably those involved in positioning the 
incoming nucleotide and the catalytic divalent ions [35,36]. The HCV-NS5B 
crystal structure was the first complete RdRp structure solved [37-39]; it 
confirmed that the general architecture of polymerases is conserved in viral 
RdRps. They adopt a typical RdRp right-hand structure comprising three 
subdomains: fingers, palm and thumb (Figure 11).  
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Fig 11. Overview of the Flavivirus RdRp structure based on WNV NS5Pol [40] as an 
example; a “Front” view is presented here in ribbon representation. Fingers, palm and 
thumb subdomains are colored in blue, green and red, respectively. The ssRNA template 
entry and the dsRNA exit are shown by black arrows. A dotted arrow points to the NTP 
entry tunnel at the back of the RdRp. Motifs A, C, E, F, the G-loop and the priming loop are 
colored in orange, yellow, grey, magenta, cyan and purple, respectively. The Asp residues 
of catalytic motifs A and C (Asp533, Asp663 and Asp664) are represented as stick models. 
The active site GDD belongs to palm domain. N-ter and C-ter indicate the termini of the 
RdRp domain. 
 
Flavivirus NS5RdRp domains display a closed conformation, where 
fingers and thumb subdomains are connected. This is a characteristic of 
RdRps and in particular of primer-independent (de novo) RdRps [41]. A 
structural element, named priming loop, provides the initiation platform. It 
belongs to the thumb subdomain and points towards the active site in the 
palm. The active site is located at the intersection of two tunnels (entry and 
exit RNA tunnels). Other de novo RdRps solved in complex with ssRNA 
28 H. Malet et al. / Antiviral Research 80 (2008) 23–35
Fig. 4. WNVRdRp overall structure. “Front” view ofWNVRdRp in ribbon representation. Fingers, palm and thumb subdomains are colored in blue, green and red, respectively.
The ss RNA template entry and the ds RNA exit are shown by black arrows. A dotted arrow points to the NTP entry tunnel at the back of the RdRp. Motifs A, C, E, F, the G-loop
and the priming loop are colored in orange, yellow, grey, magenta, cyan and purple, respectively. The aspartic acids of the motifs A and C (Asp-533, Asp-663 and Asp-664)
are represented in sticks. (For interpretation of the references to color in this figure legend, the reader is referred to the web version of the article.)
4.4. The fingers subdomain
The fingers subdomain is composed of a core and two fingertips
(Fig. 4). The core of the fingers subdomain forms a three-stranded
!-sheet absent in the structures of HCV and BVDV RdRps. The
integrity of this !-sheet is required for activity. The absence of
its first !-strand in the short WNV RdRp construct leads pre-
sumably t the isorder of the !-shee and destabilization of the
Fig. 5. Nucleotide complexes of DENV3, HCV, BVDV RdRps and de novo initiationmodel ofWNV RdRp. (A) DENV3 RdRp is shown in yellow ribbon. The triphosphate of 3′dGTP
is represented in sticks (phosphate in orange, oxygen in red). Residues coordinating it in DENV3 RdRp are represented by sticks and colored according to atom types (carbon
in yellow, phosphate in orange, oxygen in red, nitrogen in blue). Corresponding residues in HCV and BVDV RdRps are colored in green and blue sticks respectively in (C) and
(D). The DENV3 RdRp priming loop is shown in red and can be compared to the one of WNV RdRp shown in blue. The residues of the priming loop putatively involved in
the stabilization of the initiation complex, namely Trp-795 in DENV3 and Trp-800 in WNV RdRp, are represented with red and blue sticks, respectively. Catalytic aspartic
acids are represented by pink sticks and the non-catalytic ion by a light blue sphere. (B) Initiation model of WNV RdRp in the same orientation as in (A). The RNA template
and NTPs to be incorporated are shown in magenta and cyan sticks, respectively. The priming loop is shown in yellow ribbon with the proposed initiation-platform residue
Trp-800 in yellow sticks. Catalytic ions are represented by blue spheres and the catalytic aspartic acids are shown in light pink sticks. (C) HCV RdRp is shown in green ribbon
(in the same orientation as the Flavivirus RdRps in (A)). The triphosphate of dUTP bound in site i is represented by sticks. The priming loop is shown in brown ribbon with
Tyr-448 in sticks. Catalytic aspartic acids are shown in pink. (D) BVDV RdRp is shown in light blue ribbon (in the same orientation as the Flavivirus RdRps in (A)) with a GTP
in site i−1 in cyan sticks. The priming loop is represented in blue with Tyr-581 in sticks. Catalytic aspartic acids are represented in pink. (For interpretation of the references
to color in this figure legend, the reader is referred to the web version of the article.)
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template, NTPs and/or dsRNA product [42-44] suggest the following 
scenario shown in Figure 11. The first tunnel, located between the fingers 
and the thumb, should allow the ssRNA template to access the active site. 
The second tunnel, roughly perpendicular to the first, stretches across the 
entire protein. The incoming NTP should arrive from the back of the tunnel 
and, after the polymerization has started, the nascent dsRNA should go out 
through the front of this tunnel. However, as for other de novo RdRps, a 
conformational change is necessary to avoid a steric clash with the priming 
loop and allow neo-synthesized RNA to exit.  
Special features of Flavivirus NS5RdRp structures are as follows 
[45]: (i) the fingers subdomain is captured in a pre-initiation conformation 
since motif F, normally comprising the NTP-binding sites, does not form the 
upper part of the NTP tunnel but is perpendicular to its normal position and 
partially disordered. Additionally, the fingers subdomain presents a loop, 
named G-loop, which protrudes towards the active site. The G-loop harbours 
RdRp motif G in primer-dependent RdRps [46,47]. This loop may play a 
regulatory role similar to the C-terminal in other RdRps [19,48,49]. In 
summary, a concerted conformational change of motif F and G-loop of the 
trapped pre-initiation conformation is expected before Flavivirus NS5RdRp 
initiate RNA synthesis. (ii) The priming loop is provided by the thumb 
subdomain, as observed for other de novo RdRps (bacteriophage phi6, HCV 
and BVDV RdRps) [37-39,42,50], but does not host any secondary 
structure. Two aromatic residues Trp795 or His798 for DENV NS5RdRp 
(Trp800 and His803 for KUNV RdRp), may act as initiation platform 
stacking with the priming nucleotide. (iii) Two Zn ions were found, one in 
the fingers and one in the thumb subdomain. The latter is localized at a 
supposed hinge position between the thumb and the palm subdomains. It 
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might play a role in the regulation of the conformational change between 
initiation and elongation state of Flavivirus NS5RdRps. (iv) Two NLSs 
(Nuclear Localization Signal) are present at the surface of the fingers 
subdomain. The NLS of DENV-2 NS5 has been shown to be functional, and 
the transport of NS5 to the nucleus vital for virus replication [51]. In 
contrast, KUNV NS5 does not localize in the nucleus. Subtle differences in 
NLS geometry and charge distribution may be responsible for distinct 
behavior towards nuclear import in closely related viruses, but this is not yet 
deducible from the structures. It is still unknown whether NS5 of DENV-3 
localizes to the nucleus [45]. 
 
1.6 Antivirals targeting RdRp 
The four DENV serotypes have considerably expanded their 
geographic distribution in recent years. With billions of people at risk, more 
than 50 million cases, and 12500 – 25000 deaths annually, DENV is 
considered an emerging pathogen in a growing number of countries [52]. 
In particular, the presence of four DENV serotypes has complicated 
the design of vaccines because incomplete protection against one serotype 
may influence the disease outcome once infection is established by a 
different serotype, through a process referred to as antibody-mediated 
disease enhancement [53]. WNV was detected for the first time in the 
Americas in 1999; the virus is now endemic on this continent [54]. During 
the last decade, more than 36000 human cases of West Nile were reported in 
the US, including more than 1500 fatalities (Centers for Disease Control, 
2013. WNV Infection, vol. 2013. Available from: 
http://www.cdc.gov/ncidod/dvbid/westnile/index.htm).  
The Noroviruses are one of the most common causes of acute 
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gastroenteritis worldwide, infecting both children and adults. In a recent 
report from CDC (Centre for Desease Control) on outbreaks occurring in the 
US from 1991 to 2002, NV infections were recognized as the most common 
cause of viral gastroenteritis in all ages in the US, accounting for about 33% 
of all outbreaks [55]. Transmission of NV occurs via the fecal-oral route, but 
virus can be transmitted via aerosols, as observed during explosive vomiting 
[56]; [57]; [58]. The environmental resistance of NV combined with their 
high infectivity (with an infectious dose of 10–100 viral particles), facilitates 
their efficient transmission. Human susceptibility to infection by 
Noroviruses is also dependent on the blood group of the individual (A, B, 
O). The histo-blood group antigens (HBGA) are one of the recognized 
binding receptors for noroviruses [59]; [60]; [61]; [62]; [63]. 
There is thus an urgent need for antiviral drugs to treat life-
threatening infections with Flaviviruses and Noroviruses.  
Because human cells lack RdRps, this enzyme appears to be one of 
the most promising targets for antivirals against viruses that utilize 
polymerases for replication. Therefore, it is not surprising that out of the 30 
compounds that are currently marketed in the US for treatment of viral 
infections, 15 are RdRp inhibitors, especially nucleoside analogs. However, 
based on past experience with the development of drugs that are now in 
clinical use, the RdRp may prove to be the target with the best chance of 
success. The enzyme forms part of a multimeric complex that plays a crucial 
role in viral genome replication, but because it is encoded by the viral 
genome, and has no cellar counterpart, there are no toxicity issues [45]. 
Viral polymerases have been clinically validated as the target of both 
nucleoside (NI) and non-nucleoside inhibitors (NNI). Nucleoside analogues 
are generally converted to nucleotide analogues by host cell kinases. NIs 
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target the active site of the polymerase. They can either compete with natural 
NTP substrates or/and act as ‘chain terminators’ [64], or cause a mutational 
‘error catastrophe’ by being incorporated into the elongating nascent RNA 
molecule [65]; [66]. NIs have been discovered through a rational search of 
substrate analogues, and they often possess a broad-spectrum antiviral 
activity. They also provide the greatest barrier to resistance [67]. Few 
molecules have been reported so far as effective RdRp NIs. Before a 
nucleoside can terminate a viral RNA chain, it must penetrate into the cell, 
be converted to its triphosphate derivative, be recognized by the viral 
polymerase, and incorporated into the viral RNA chain. Therefore, 
nucleosides have complex and unpredictable SAR (Structure Activity 
Relationship) [68].  
The second category of compounds, NNIs, bind mainly to allosteric 
surface cavities of the target polymerase. They may induce a conformational 
change that causes the polymerase inactivation, or trap it in a given 
conformation avoiding an essential conformational transition between 
initiation and elongation. Allosteric inhibition has been shown to be a highly 
effective strategy [69] that can be improved by rational structure-based 
design [70]. 
Inhibitors of protein–protein or protein–RNA interactions involving 
viral polymerases are less explored as antiviral drugs. Effective antiviral 
molecules that seem to inhibit interactions of the viral polymerase within the 
replicative complex have been reported, e.g. for herpes virus [71] and 
pestiviruses [72]; [73]. As a whole, the search for antivirals against RdRps 
and RNA replication can be considered to be in its initial phase and RdRp 
crystal structures will help advancing the whole process.  
Our knowledge on Flavivirus RdRp structures allows us to perform a 
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molecular surface shape analysis, with the aim to identify cavities that could 
potentially correspond to allosteric inhibitor binding sites. An analysis of the 
surface of the DENV and WNV RdRps identified two conserved cavities 
(named cavity A and B) on the surface of the enzyme that could potentially 
be targeted by small-molecule inhibitors [45]. These cavities are both 
located within the thumb domain that includes the priming loop (Figure 12).  
Cavity A is the largest with a volume of 169 Å3. Residues building 
the cavity are listed in Figure 12C. In particular, Tyr867 forms the upper part 
of the cavity and could promote a stacking interaction with a ligand 
containing an aromatic ring. Residues 810–814 (main chain atoms), which 
constitute the end of the priming loop, form the lower part of the cavity. 
Binding of a compound in that cavity could thus potentially damage the 
conformational change of the priming loop required for the transition to 
elongation. Cavity B is located on top of the thumb and has a volume of 
77 Å3. Main residues lining this cavity are listed in Figure 12C. Three 
additional cavities are present only in WNV RdRp, located in the thumb 
(cavity C and D), and in the fingers subdomain (cavity E). The size and the 
shape of the predicted cavities are compatible with the binding of small-
molecule inhibitors in potential allosteric sites, they could thus represent 
“druggable pockets”. Especially cavity A and B, predicted for both DENV-3 
and WNV RdRp, might be exploited as a starting point for structure-based 
drug design; a first possible approach being virtual screening.  
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Fig 12. Locations of the cavities and putative allosteric sites on WNV RdRp. WNV RdRp 
cavities found by two programs, Pass and CastP, are represented in color on the surface and 
are named by letters. Cavities A and B were also found on DENV-3 RdRp. (A) “Front” 
view showing cavity A. (B) “Back” view showing cavities B, C and D. (C) DENV-3 
residues building the putative allosteric sites A and B are reported. 
 
Such type of shape/surface analysis hasn't been performed for 
Norovirus polymerases and just NI inhibitors are known against NV RdRps. 
Recently, two NNIs have been descovered: suramin and NF023 [74]. The 
crystal structures of mNV RdRp bound to each of the two inhibitors showed 
a common inhibitor binding site, close to the protein active site. In 
particular, the cleft occupied by the inhibitors is lined with several conserved 
positively charged amino acids, likely building the access route for the 
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incoming NTP that will be linked to the nascent RNA chain. Both NF023 
and suramin may interfere with (i) entrance of new NTPs into the protein 
active site, by hindering the access channel and reducing the protein affinity 
for NTPs, due to the negatively charged sulfonates; (ii) the correct 
positioning of NTPs required for the formation of each new phosphodiester 
bond, and (iii) the exit route of the newly formed oligonucleotide chain, due 
to electrostatic repulsion.  
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2. Aims of my Thesis Project 
RNA virus infections kill millions of humans annually, largely due to 
the lack of suitable vaccines and drugs to control them. The work carried out 
during my PhD has been developed in the context of the European project 
SILVER (Small-molecule Inhibitor Leads Versus Emerging and 
neglected RNA viruses). The SILVER project is based on a consortium 
arising from the coordination of European and Asiatic leading molecular 
virologists, structural biologists, medicinal chemists and bioinformaticians. 
The ultimate aim of SILVER is to generate a state-of-the-art drug design 
programme to face new and emerging diseases caused by RNA viruses. 
SILVER started in 2010 and since the beginning it required the 
collaboration of many groups, connecting chemistry, biochemistry, 
molecular biology, in vitro cell-based assay, in vivo animal-based assay, 
structural biology and computational studies (Figure 13).  
 
Fig 13. The SILVER project connects different research lines in the field of drug design and 
discovery against RNA viruses. The structural contribute is crucial for the project, providing 
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the basic information for the design and optimization of all the compounds synthesized, and 
for the analysis of protein/inhibitor complexes. 
 
The SILVER project focuses its activities on selected medically 
important RNA viruses for which the development of drugs is considered 
essential (Dengue, entero- and paramyxoviruses), whereas other relatively 
neglected and emerging RNA viruses are explored to identify the most 
promising viral protein targets and antiviral compounds. 
My PhD work focused on the study of the proteins involved in viral 
replication, in particular I worked on the identification of new NNIs against 
Flaviviruses (Dengue and West Nile) and Noroviruses (Human and Murine), 
using RdRp as main target.  
My project targets challenging biological questions: 1) what kind of 
features the RdRp NNIs must hold, 2) how can we improve the RdRp 
interaction with already known inhibitors, 3) how can we improve cell 
permeability of already known inhibitors, 4) which are the inhibitory kinetic 
mechanisms of the identified compounds.   
These goals have been tackled using different experimental 
approaches: in silico docking searches, X-ray structural biology, and in vitro 
polymerase assays (Figure 14).  
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Fig 14. The PhD project has been developed in different steps. First of all the discovery of 
new potential inhibitors using in silico docking tecnique. To test the potential inhibitors, the 
targeted enzyme has to be expressed, purified and characterized. The protein activity is 
tested using a fluorimetric assay. When the potential inhibitors are active, their kinetics is 
studied. The last step is crystallization of RdRp-inhibitor complexes, and their 3D-structure 
analyses. 
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3. Main Results 
 
3.1 Structural and functional analysis of Norovirus RdRp inhibitors 
Naf2 and PPNDS 
The NNIs known to date as NV RdRp inhibitors are suramin and 
NF023 [74]. The two molecules display low IC50 values (suramin/mNV 
70±3nM, suramin/hNV 24.6±0.8nM; NF023/mNV 200±2nM, NF023/hNV 
71.5±0.9nM) but unfortunately, the molecular size and the high number of 
charged groups hamper cell permeability, with the result that the compounds 
are not active in cell-based assays. 
Starting from these inhibitors, in order to reduce both the molecular 
weights and the number of the charged groups, I first investigated a fragment 
of the two molecules that, according to the crystal structures, mapped to the 
less flexible region of the suramin/NF023 binding site, within the enzyme 
active site. I focused on naphthalene-1,5- disulphonic acid (Naf2), which is 
the naphtalene head of suramin, and/or NF023 (Figure 15).  
Fig 15. (a) Chemical structure of NF023, (b) chemical structure of suramin, and (c) 
chemical structure of Naf2 
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I performed the polymerase inhibition assays on both murine and 
human NV RdRp. The two proteins were expressed and purified as 
described in [75] in Prof. Rohayem’s lab. The enzymatic activity test is 
based on an in vitro RNA synthesis fluorimetric assay (see Material and 
Methods in Tarantino et al., Naphthalene-sulfonate inhibitors of human 
norovirus RNA-dependent RNA-polymerase, (2014) Antiviral Research 102: 
23–28- Part II). Naf2 displayed low inhibitory activity against the enzymes 
(IC50 values: Naf2/mNV 14147±1543nM, Naf2/hNV 15500±800nM); 
moreover, analysing the dose-response curves, it is clear that the number of 
bound inhibitor molecules is higher than 1.  
The crystal structures of both NV RdRps, in the presence of Naf2, 
confirm the presence of an additional Naf2 molecule, located in the thumb 
domain, i.e. an additional binding site (site B), besides the one characterized 
for NF023/suramin (site A) (Figure 16). 
Fig 16. Crystal structure of hNV-RdRp bound to two Naf2 molecules, in the A-site and in 
the B-site. The overall structure of hNV-RdRp is shown as a cartoon: N-terminal domain 
(blue), thumb (red), fingers (yellow) and palm (green). The picture on the right is rotated by 
90 degrees around the vertical axis. 
 
hNV-RdRp crystallization experiments were performed in presence
of NAF2 (see Section 2for details). The hNV-RdRp crystals were
soaked in 30 mM NAF2 before cryo-cooling, The crystal (belonging
to the orthorhombic space group I222, with one molecule per
asymmetric unit) diffracted to a maximum resolution of 2.04 Å,
and the structure was refined to a final crystallographic R-factor
of 17.0% and R-free of 22.3% (Table 2). The first refinement cycles
showed residual electron density compatible with a NAF2 mole-
cule located in a positively charged cleft within the thumb domain
(Fig. 3a and b), built by an a-b-loop-a motif; inspection of the en-
zyme structure confirms that this site (hereafter, the B-site) is dif-
ferent from the binding site where suramin and NF023 inhibitors
were located (hereafter, the A-site). In the B-site, the negative
charges of NAF2 sulfonates are balanced by Arg419 and Arg436;
the naphthalene ring is sandwiched between Gln414 and Gln439
(forming an intertwined hydrogen bond network together with
Asn505), on one side, and Phe28 and Arg419, on the other
(Fig. 3b). Additional polar interactions involve the side chains of
Asn505 and Thr418 and the main chain nitrogen of Arg419. Inspec-
tion of the hNV-RdRp/NAF2 crystal structure in comparison to the
enzyme 3D structure in the absence of inhibitors (pdb-id: 2B43,
r.m.s.d. 0.70 Å, over 499 Ca pairs) shows that, upon NAF2 binding,
the protein undergoes only slight structural rearrangements at a
few residues, and at the last two C-terminal residues, Asn505
and Glu506, visible in the electron density.
3.2.2. Inhibitor binding to the A-site
Further inspection of difference Fourier maps revealed residual
electron density compatible with one NAF2 molecule in the A-site
(Fig. 3a and c), i.e. at a location very close to the site occupied by
the naphthalene-sulfonate moiety of NF023/suramin, in the fingers
domain (Fig. 3c; Mastrangelo et al., 2012). Lys171, Lys174, Lys180
and Arg182 stabilize the inhibitor negative charges; the sulfonate
groups establish H-bonds with Gln66 and the main chain N atom
of Lys171. Additionally, the naphthalene ring makes p-cation inter-
actions with Lys174 and Arg182 (Fig. 3c).
3.3. Crystal structure of hNV-RdRp bound to PPNDS
In a previous virtual screening search targeting a wide region
around the hNV-RdRp active site, we identified PPNDS, a com-
pound hosting a naphthalene disulfonate moiety, among other po-
tential NV-RdRp inhi itors (Mastrangelo et al. 2012). Analysis of
the simulated structure showed that PPNDS would locate in a
Fig. 3. (a) Crystal structure of hNV-RdRp bound to two NAF2 molecules in the A-site and B-site; the overall structure of hNV-RdRp in cartoon: N-terminal domain (blue),
thumb (red), fingers (yellow) and palm (green). The picture on the right is rotated by 90 degree around the vertical axis. (b and c) Details of the hNV-RdRp/NAF2 interaction in
the B-site (b) and A-site (c); transparent surface colored by electrostatic potential (program APBS2; (Baker et al., 2001)); amino acids involved in the interaction with NAF2 are
labeled. Figures created using PyMol (http://www.pymol.org). (For interpretation of the references to color in this figure legend, the reader is referred to the web version of
this article.)
Fig. 2. (a) Reaction velocity plot as a function of the RNA concentration, s in
absence of the inhibitor, d in presence of 0.45 lM of PPNDS and h in presence of
1 lM of PPNDS. (b) Lineweaver–Burk double reciprocal plot for the no competitive
inhibition mechanism of hNV RdRp activity by PPNDS, relative to RNA substrate.
26 D. Tarantino et al. / Antiviral Research 102 (2014) 23–28
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In the B site, the negative charges of Naf2 sulfonates are balanced by 
arginine residues and the naphthalene ring is sandwiched between two 
glutammine residues. This site is close to the dsRNA exit channel. 
To better characterize the new potential inhibitory site, we selected a 
structurally related molecule: Pyridoxal-5’-phosphate-6-(2’-naphthylazo-6’-
nitro-4’,8’-disulfonate) tetrasodium salt (PPNDS, Figure 17) which from a 
previous docking search was suggested to fall in a region close to the newly 
recognized binding site (site B).  
Fig 17. Chemical structure of PPNDS. 
 
I performed the RdRp inhibition assays using PPNDS (see Material 
and Methods in Tarantino et al., Naphthalene-sulfonate inhibitors of human 
norovirus RNA-dependent RNA-polymerase, (2014) Antiviral Research 102: 
23–28; Croci et al., PPNDS inhibits murine Norovirus RNA-dependent 
RNA-polymerase mimicking two RNA stacking bases, (2014) FEBS Letters 
588: 1720–1725- Part II), which displayed low micromolar inhibitory 
activity versus both human and murine Norovirus RdRps (IC50 
PPNDS/mNV 800±30nM, PPNDS/hNV 1000±90nM). I also analysed the 
kinetic mechanism of hNV RdRp inhibition by PPNDS with respect to the 
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substrate poly(C)/oligo(G)12, increasing the amount of the substrate and of 
the inhibitor. The Lineweaver-Burk plots, derived from the inhibition curves 
analysis, highlighted a non-competitive inhibition mechanism with respect to 
the substrate, with a Ki value of 0.52±0.05µM, indicating that the inhibitor is 
able to bind the free enzyme as well as the enzyme-substrate complex.  
I performed also a thermofluorimetric assay in order to verify 
whether the selected compounds might induce some form of destabilization 
or denaturation of the enzyme. In general this is reflected by a variation of 
the protein melting temperature (Tm). hNV RdRp in the presence or absence 
of Naf2 displays the same Tm (respectively 36.9±0.5 ºC and 37.5±0.4ºC). In 
contrast, in hNV RdRp/PPNDS complex, the Tm increases slightly relative to 
hNV RdRp Tm (respectively 37.0±0.5ºC and 41.0±2.0ºC), implying some 
protein stabilization induced by the presence of the inhibitor. 
The crystal structures of both human and murine NV RdRp/PPNDS 
were obtained only after soaking the protein with inhibitor in presence of 
dsRNA and GTP. This suggests that inhibitor binding to the protein requires 
local structural changes related to events in the catalytic cycle. NV 
RdRp/PPNDS complex crystal structures showed that the inhibitor bound to 
the secondary site blocking the exit of the newly synthesized RNA, 
confirming the relevance of this site for the inhibition of the enzyme. 
However, several differences between human and murine Norovirus 
RdRp/PPNDS structures were observed.  
In the PPNDS/hNV RdRp complex structure, only a single molecule 
of inhibitor bound to site B was observed (Figure 18). The overall structure 
of the whole enzyme bound to PPNDS appears slightly more compact if 
compared to that of the inhibitor-free protein. Such overall effect is related 
to a small displacement of both the finger and the thumb domains toward the 
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active site, as a closing hand, and this is likely due to the interaction of the 
protein with dsRNA. In fact, the crystal structure shows residual electron 
density hosted between the fingers and thumb domains compatible with two 
or three RNA nucleotides, which have been only partially modeled in the 
refined structure, due to electron density ambiguities.  
Fig 18. (a) Crystal structure of hNV RdRp bound to PPNDS in cartoon. PPNDS (orange 
carbon atoms) and a fragment of ssRNA, partially modeled into observed electron density 
(gray) are shown as sticks. (b) Same as (a) with protein surface colored by electrostatic 
potential. 
 
In contrast, in the PPNDS/mNV RdRp complex structure two 
molecules of the inhibitor were found into the new site, blocking dsRNA 
formation. In particular the two molecules bound to mNV RdRp display an 
evident antiparallel stacking orientation, roughly aligned along the main 
alpha helices of the thumb domain (Figure 19a). They adopt an orientation 
rotated by about 60º relative to that observed for the single PPNDS molecule 
in hNV RdRp complex (Figure 19b,c).  
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Fig 19. (a) mNV RdRp/PPNDS structure. The two molecules of the inhibitor are in 
antiparallel stacking interaction each other, (b) hNV RdRp/PPNDS structure. The single 
PPNDS molecule is rotated by about 60º relative to that in mNV RdRp, (c) superposition of 
the PPNDS molecules 1 and 2 bound to mNV RdRp (in orange and yellow) and PPNDS 
molecule bound to hNV RdRp (in grey). 
 
3.2 Structural and functional analysis of suramin synthesis 
intermediates 
In addition to the analysis of structurally related molecules, to reduce 
the molecular dimensions and the charged groups present in suramin, I 
planned chemical modifications of the molecule. The crystal structure of 
mNV RdRp in complex with suramin showed that only two of the three 
sulphonate groups of the suramin naphthalene rings establish ionic 
interactions with basic residues of the enzyme. On the basis of such 
structural information, in collaboration with Prof. Hwu’s group, from 
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National Central University of Jhongli (Taiwan), we modified suramin 
removing one sulphonate group and isolating several intermediates of the 
chemical synthesis process (Figure 20). 
Fig 20. Suramin derivative 8 synthesis. Total synthesis of Suramin derivative 8 from 
commercially available starting materials. The Suramin molecule (9) is also shown for 
comparison. 
 
I characterized compound 8 (Cpd8) together with lower molecular 
weight synthetic reaction intermediates using a fluorescence-based assay 
(see Materials and Methods in Croci et al., Structural Bases of Norovirus 
RNA Dependent RNA Polymerase Inhibition by Novel Suramin-Related 
Compounds, (2014) PLoS ONE 9(3): e91765- Part II). 
The synthetic intermediates are less potent inhibitors than suramin, in 
particular against hNV RdRp (Table 4).  
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 IC50 (nM) 
Compound mNV RdRp hNV RdRp 
3 700±10 1780±70 
4 160±7 1100±200 
6 115±15 1000±90 
7 160±6 1100±50 
8 60±4 28±2 
Suramin (9) 70±3 27±3 
 
Table 4. IC50 values of Suramin derivatives and Suramin (9) against mNV and hNV RdRps. 
 
Cpd8 showed the same IC50 values of suramin. Since the structures 
of the two molecules are very similar, we assumed that Cpd8 binds the 
proteins in the same manner. 
In order to analyze in details the interaction of the lower molecular 
weight intermediates hosting one sulphonate head with RdRps, I crystallized 
the enzyme with the compound showing the best inhibition, 4-[4-Methyl-3-
(3-nitrobenzamido)benzamido]naphthalene-1,5-disulfonic Acid Disodium 
Salt (Cp6). Cp6 shows a logP higher than the other intermediates (logP -
1.64) (see Croci et al., Structural Bases of Norovirus RNA Dependent RNA 
Polymerase Inhibition by Novel Suramin-Related Compounds, (2014) PLoS 
ONE 9(3): e91765- Part II). LogP is the logarithm of the ratio of 
concentrations of a compound in two immiscible phases at equilibrium. This 
coefficient is a measure of the difference in solubility of the compound in 
these two phases, and is prognostic to cell permeability. 
In the high resolution crystallographic analysis of Cpd6 in complex 
with hNV RdRp (hNV/Cpd6: 2.02Å resolution), the naphthalene sulphonate 
head of Cpd6, the linked amido group and the phenyl methyl group were 
found in a location different from the suramin binding site (site A), but in the 
same binding site of PPNDS (site B). Density for the remaining part of the 
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compound was not visible due to conformational disorder. The unmodelled 
tail of Cpd6 would be hosted in the polar central region of the enzyme which 
accommodates dsRNA during elongation. This region is wide enough to 
allow conformational flexibility of the second half of the inhibitor, in 
agreement with the lack of an interpretable electron density signal (Figure 
21). In mNV RdRp/Cpd6 crystal structure (resolution 2.30Å), the 
naphthalene disulphonate head binds to the same location identified for hNV 
RdRp and the entire compound is modelled in the electron density. The 
compound is rotated of about 20° in comparison to that in hNV RdRp 
structure. 
Fig 21.  (a) Superposition of the crystal structures of hNV RdRp in cartoon (magenta) 
bound to Cpd6 (carbon atoms in yellow) in sticks, onto mNV RdRp in cartoon (blue), bound 
to Cpd6 (carbon atoms in green) in sticks. (b) Detail of the superposition of hNV and mNV 
RdRps. The interacting amino acids are shown as sticks. 
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3.3 Structure and biochemical characterization of a Flavivirus RdRp 
inhibitor 
Since the work showed in this paragraph is still ongoing, the results 
are not published yet. For reasons of confidentidity no chemical structures 
can be shown. 
In a search for new potential NNIs Flaviviral inhibitors, I chose to 
explore a wide region around the active site of Dengue RdRp as the targeted 
inhibitor binding site. A virtual screening procedure was firstly set up with 
the aim of testing a library of compounds. The crystal structure of DENV3 
RdRp (pdb id: 2J7U [40]) was employed as a model for the protein, 
selecting the entry RNA template site as the centre of the docking search. 
This region (~15.2 nm3; Figure 22) was explored using a library of 203 
compounds (UNIPG library) (Figure 23) as described in Flavivirus RdRp 
Materials and Methods paragraph - Part III.  
 
Fig 22. In silico docking of UNIPG library into DENV-3 active site. The box highlights the 
region explored (15.2nm3). This region includes the active site residues GDD belonging to 
palm domain and the priming loop belonging to thumb. GDD and priming loop are shown 
in sticks. 
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Molecules belonging to UNIPG library were designed by Dr. 
Manfroni’s lab as potential inhibitors against the Flaviviridae family. The 
docking search produced a list of compounds with predicted binding free 
energy values (∆G) ranging between - 5.65 kcal/mol and -10.05 kcal/mol. 
Among the top compounds ranked by the docking search, we selected HeE1-
2SO2 (∆G = -10.05 kcal/mol) and HeE1-2Tyr (∆G = -9.52, kcal/mol) to be 
used for in vitro testing of inhibitory activity versus West Nile and Dengue 
virus RdRps. 
 
Fig 23. UNIPG library is composed of heterotricyclic compounds with a scaffold core and 
three different substituents. 
 
In vitro RNA synthesis assays were performed using a fluorescence-
based assay (Flavivirus RdRp Materials and Methods paragraph - Part III). 
The results have been analyzed with GraFit5 and IC50 values have been 
calculated. Under these experimental conditions, HeE1-2SO2 and HeE1-
2Tyr resulted to inhibit RdRp activity with IC50 values in the micromolar 
RdRp targeting antivirals 
 47 
range; in particular HeE1-2SO2 /DENV-3 RdRp 2.8±0.5µM and HeE1-
2SO2 /WNV RdRp 2.5±1.3µM, whereas HeE1-2Tyr /DENV3 RdRp 
3.5±0.2µM and HeE1-2Tyr /WNV RdRp 3.4±0.4µM. 
I also analyzed the kinetic mechanism of RdRps inhibition by HeE1-
2Tyr, for both DENV3 RdRp and WNV RdRp. The Lineweaver–Burk plots 
derived from inhibition curves for both RdRps (Figure 24) highlighted a 
non-competitive inhibition mechanism relative to poly(rC) as substrate, with 
a DENV RdRp/ HeE1-2Tyr  Ki value of 0.64 ± 0.08 µM and WNV RdRp/ 
HeE1-2Tyr  Ki value of 1.59 ± 0.50 µM.  
 
Fig 24. Lineweaver–Burk double reciprocal plot for the non-competitive inhibition 
mechanism of DENV3 RdRp activity by HeE1-2Tyr, relative to Poly(rC) as substrate. 
  
The specificity of the HeE1-2Tyr inhibition was verified by 
excluding any off-target effects on the overall native protein fold, such as 
ligand-induced destabilization/aggregation/denaturation. To this aim, 
thermal denaturation analysis using Sypro-orange as the fluorescent probe 
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were performed. The WNV and DENV RdRps Tm resulted to be essentially 
the same in the absence (WNV RdRp Tm=46.3±0.4 °C; DENV RdRp 
Tm=39.6±0.1 °C) or in the presence (WNV RdRp Tm=47.3±0.3 °C; DENV 
RdRp Tm=39.6±0.1 °C) of HeE1-2Tyr. 
All the thermofluorimetric results proved that the RdRps inhibition is 
not due to inhibitor-linked adverse effects on enzyme. 
HeE1-2Tyr and HeE1-2SO2, together with other 13 analogues 
present in the UNIPG library, were tested for their antiviral activity in cell 
assays (HeK 293/Vero E6). Six of the selected compounds showed high 
cytotoxicity to uninfected cells, and thus were abandoned; eight compounds 
did not show any activity, probably due to low cell permeability, while 
HeE1-2Tyr proved to be a very promising hit. 
Upon treatment of infected Vero E6 cells, HeE1-2Tyr was able to 
inhibit an Ugandan strain of WNV as well as Dengue viruses (Table 4). The 
cytotoxicity of HeE1-2Tyr versus Vero E6 cells was 75µM, allowing a 
reasonably good selectivity index for a starting hit compound. In human 
HeK 293 cells, the cytotoxicity of HeE1-2Tyr was slightly higher (CC50 ≈ 
40µM) and the compound was found to inhibit a clinical strain of YFV with 
an IC50 ~2.6µM (Table 5) (These data were obtained in Prof. Querat’s lab, 
University of Aix, Marseille). 
 
Virus HeE1-2Tyr IC50 (µM) 
YFV (Bolivian clinical strain) 2.6 
WNV 2.6 
DENV-1 8.8 
DENV-2 8.8 
DENV-3 10.7 
DENV-4 5.6 
JE >10 
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Cells CC50 (µM) 
Vero E6 75 
HeK 293 40 
 
Table 5. IC50 and CC50 values of HeE1-2Tyr against several Flaviviruses.  
 
I was able to grow WNV RdRp crystals, as described in Flavivirus 
RdRp Materials and Methods paragraph - Part III, and soaked them with 
HeE1-2Tyr and HeE1-2SO2  (15mM and 5mM final concentrations, 
respectively). The crystals soaked with HeE1-2SO2 (belonging to the space 
group I222, with only one molecule per asymmetric unit) diffracted at 
maximum resolution of 2.7Å, while the crystal soaked with HeE1-2Tyr 
diffracted at a very low resolution (4.2Å). We solved the structures by 
molecular replacement (the search model was pdb 2HFZ) and refined to a 
final crystallographic R-factor/R-free values of 22.58/26.74% for WNV 
RdRp/HeE1-2SO2.  
Although the electron density of the inhibitor is not clear enough, I 
could deduce that HeE1-2SO2 interferes with the location of the RdRp 
priming loop that appears to be disordered in the crystal structure of the 
complex (Figure 25). The priming loop is composed of residues 796-809 in 
WNV RdRp; in our refined structure WNV RdRp residues Trp800, Ser801, 
Ile802 and His803 are not visible probably because they adopt various 
conformations upon interaction with HeE1-2SO2.  
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Fig 25. (a) Inhibitor-free WNV RdRp (2.7Å) (green) in which all the residues belonging to 
priming loop are visible (red). (b) WNV RdRp/HeE1-2SO2 (2.64Å) complex in light blue. 
Some priming loop residues do not show electron density in the presence of the inhibitor. 
 
My hypothesis is enhanced by the crystal structure of WNV RdRp/ 
HeE1-2Tyr. Also in this structure three residues (Thr799, Trp800 and 
Gly805) lack proper electron density. Such evidence is in agreement with 
the in silico docking searches for the binding site of the two compounds, 
which are predicted to interact with residues of the priming loop and with 
one active site residue (Asp664), between the thumb and the palm domains. 
Since Trp800 and His803 side chains may help orienting the base of the 
priming nucleotide via a stacking interaction during the catalytic cycle, their 
conformational perturbation could explain the loss of activity caused by 
HeE1-2SO2/HeE1-2Tyr.   
 
  
priming 
loop  
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4. Conclusions and Future Prospects 
In the three years of my PhD project, I have been involved in the 
identification of new non-nucleotide-like inhibitors against Noroviruses 
(murine and human NV) and Flaviviruses (West Nile virus), using RNA 
dependent RNA polymerase (RdRp) as the main target.  
Noroviruses are the major cause of epidemic viral gastroenteritis, 
worldwide, responsible for about 200.000 deaths/year, however no vaccines 
nor antivirals are available. To this purpose, starting from a previous work 
[74] in which the structures of mNV RdRp in complex with suramin and 
NF023 were solved, I first analyzed the potential role of the naphtalene-head 
of the inhibitors (Naf2). Suramin and NF023 binding site (site A) is located 
along the access pathway of NTPs to the enzyme active center. Accordingly, 
this site is lined with positively charged residues whose conformational 
flexibility helps promoting the diffusion of NTPs toward the catalytic site. 
Such structural features are unlikely to make this inhibitor binding site an 
ideal target region for structure based drug optimization. Although 
enzymatic assays showed that the selected fragment retains marginal 
inhibitory activity, the NV RdRp/Naf2 complexes revealed an unexpected 
binding site (besides the already characterized site A) for Naf2, located in 
the RdRp thumb domain (site B). Interestingly, the site B is located in a 
position that is roughly structurally equivalent to the benzothiadiazine 
inhibitor binding site in the Hepatitis C Virus RdRp [76]; [77]; [78]. Naf2 
binding to two distinct sites is also suggested by the inhibition mechanism 
analysis, which shows a Hill coefficient higher than 1. In order to further 
characterize the site B, we selected PPNDS, a naphthalene sulfonate-based 
compound. PPNDS is able to inhibit the NV RdRp activity with an IC50 
close to that observed for suramin or NF023. The crystal structure of the 
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hNV RdRp/PPNDS complex shows that the compound is anchored to the 
protein mostly through its naphthalene moiety. The improved inhibitory 
efficacy, relative to Naf2, is likely dependent on PPNDS pyridoxal moiety 
that extends toward the enzyme active site. The relevant inhibitory 
difference between Naf2 and PPNDS in hNV RdRp are probably due to the 
fact that PPNDS can fix the C-terminal end of the enzyme inside the active 
site, blocking access of both the ssRNA template and the NTPs.  
In mNV RdRp/PPNDS complex crystal structure, instead, two 
PPNDS molecules bind the enzyme at site B. The two inhibitor molecules 
display an antiparallel stacking interaction and adopt an orientation rotated 
by about 60° relative to that observed for the single PPNDS molecule bound 
to hNV RdRp. Such significant changes are likely related to the insertion of 
the C-terminal segment of the hNV RdRp (aa. 490-506) inside the enzyme 
active-site region. In mNV RdRp the C-terminal segment is disordered after 
Gly488, thus leaving more room in the active site region for the incoming 
inhibitory molecules. 
It must be stressed that the two PPNDS molecules fall in a location 
close to the region that would be taken by the newly formed ssRNA chain, 
as inferred by superposition with the structure of hNV RdRp bound to 
dsRNA (Figure 26). In particular PPNDS-1 and PPNDS-2, after 
superimposition, fall on nucleotides n-2 and n-1 respectively (n is the 
nucleotide that will be linked to the incoming NTP). The structural results on 
mNV RdRp show that PPNDS can display properties allowing it to mimic 
the stacking interaction of two linked bases in RNA.  
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Fig 26. Detail of superposition of mNV RdRp in complex with PPNDS molecules (in 
yellow and orange) on hNV RdRp bound to dsRNA (in blue; n=nucleotide; pdb ID 3BSN). 
 
Such a RNA-like property of the inhibitor might be improved by 
covalently linking the phosphate moieties of the two PPNDS molecules that 
are found in close contact in the X-ray structure.  
 
Concerning the issue of cell permeability for suramin and NF023, a 
strategy adopted was to synthesize suramin derivatives with a lower number 
of charged groups. The solubility of chemical entities in water plays an 
important role in their development as a lead for new drugs, and it is related 
to the structure–activity relationship. The apparent partition coefficient (P) is 
a useful parameter for understanding the behavior of drug molecules. Often 
it is used to predict the distribution of a drug compound in a biological 
system, the log P value being related to absorption, excretion, and 
penetration [79]. The measurement of the apparent partition coefficient 
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provides a simple in vitro method to predict the behavior of a compound in 
the body and to select the most promising drug candidates from a large pool 
of ionizable compounds. Among the compounds considered, Cpd6 showed a 
better hydrophobicity than suramin (log P –1.64 versus  –3.42, respectively). 
Our analysis on the NV RdRp/Cpd6 complex 3D structure shows 
that the sulphonate groups on the naphthalene sulphonic head interact with 
the RNA binding loop (residues 433–440). The crystal structures of hNV 
RdRp/RNA complexes (3BSO and 3H5X) [20]; [21] revealed significantly 
different locations in the RNA-binding loop relative to the free RdRp, 
showing specific RNA-induced conformational changes of this loop [22]. 
Binding of Cpd6 might freeze the loop of hNV RdRp in the conformation 
found in the free enzyme, hindering efficient RNA binding. 
In the hNV RdRp/Cpd6 complex, the inhibitor electron density fades 
rapidly after the amido group linked to the naphthalene di-sulphonate 
moiety. Thus, the lower inhibitory potency of Cpd6 vs. hNV RdRp may be 
linked to failure of establishing enzyme/inhibitor stabilizing interactions 
along the whole inhibitory molecule, which appears to remain flexible for 
about 50% of its scaffold. 
On the contrary, in the mNV RdRp/Cpd6 structure, the inhibitor 
could be completely modeled because of the different disposition of the 
naphthalene head due to loss of interaction with residue His433. The 
additional interactions of Cpd6 with residues Arg392 and Arg393 are in 
agreement with the higher potency of Cpd6 versus mNV RdRp relative to 
hNV RdRp.  
The newly discovered NV RdRp inhibitor binding site, mapped by 
Cpd6 and by PPNDS, together with the different conformational behaviors 
displayed by Cpd6 bound to NV RdRps, appear as two novel structural bases 
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to be exploited for the design and development of more potent and selective 
hNV RdRp inhibitors. 
 
In parallel to the Norovirus work, I focused on Flaviviruses that are 
emerging pathogens of increasingly public health concern in the world. For 
most Flaviviruses such as Dengue virus and West Nile virus neither vaccine 
nor antiviral treatment is available [45]. Flavivirus RdRp is essential for 
viral replication also because its priming loop constitutes a platform 
stabilizing the RNA synthesis initiation complex [40]. Conformational 
changes of this loop, not yet characterized by structural studies, are 
presumably required to shift to an RNA synthesis elongation mode. Residues 
in the priming loop (residues 796-809 in WNV RdRp, and 782-809 in 
DENV RdRp) are used to orient the base of the priming nucleotide via a 
stacking interaction. In WNV RdRp, Trp800 and His803 may perform this 
function [40]. 
Such information brought us to design small-molecules (NNIs) that 
could bind Flavivirus RdRps in the entry RNA template channel. We have 
designed different molecules and selected, through in silico docking, 
potential inhibitor compounds. In vitro enzymatic assays confirmed our in 
silico predictions, showing HeE1-2SO2 and HeE1-2Tyr as good inhibitors. 
The properties of these molecules have been shown also in in vivo cell based 
assays. The study of the RdRp/HeE1-2Tyr and RdRp/HeE1-2SO2 3D 
structures complexes helped us to better understand and explain the 
mechanism of inhibition of the molecules. In fact, the structures show that 
both compounds (although with poor electron density) interfere with the 
location of the RdRp priming loop (in agreement with the in silico 
predictions), which is disordered in the crystal structures. The fact that in 
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Flavivirus RdRps, and in particular in DENV RdRp, the priming loop has a 
clear density, suggests that it is well structured in the absence of RNA [70], 
supporting our hypothesis that HeE1-2SO2/HeE1-2Tyr inhibitory features 
could depend on the interference between the compounds and the priming 
loop. In this way the protein loses its capability to orient the nucleotide.  
This study answers some of the biological questions posed by 
discovering NNIs that interact with the targeted protein in a strategic binding 
site (close to RNA exit channel) and host charged groups and rigid moieties. 
The improvement of the inhibitory properties presented by these molecules 
will require a reduction of the number of charged groups and of the 
molecular size. 
In conclusion, the results achieved during my PhD project highlight 
the potential of structure-based rational drug design also for antiviral 
research; they will also be instrumental for the identification of new drug 
candidates able to interfere with essential steps of RdRp activity. 
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7. Introduction to another approach to find antivirals: in vitro cell-based 
assay 
Over the past years, there has been a growing trend toward the use of 
cell-based assays, in particular for pharmaceutical research and drug 
development. Cell-based assays refer to the use of living cells as discovery 
tools. This includes a variety of assays that measure cell proliferation, 
toxicity, motility and morphology. Insights from such cellular assays have 
been shown to facilitate drug discovery, saving considerable time and cutting 
costs.  
The cell-based assays applied to antiviral research offer a broad range 
of applications: 
• To discover compounds with antiviral activity using cell-culture 
based assays for virus replication 
• To validate activity of hit compounds delivered, and support the hit-
to-lead optimization process 
• To identify targets and unravel mechanisms of action of newly 
discovered antiviral inhibitors. 
 
To test PPNDS on mNV and other compounds on Flaviviruses and 
Coronaviruses, I spent two months of my PhD at The Catholic University 
Leuven (KU, Leuven, Belgium) at the Department of Virology, in Prof. 
Johan Neyts’ lab, a partner in the SILVER project. 
 
7.1 Cell-base assays with PPNDS and PPNDS in liposomes 
A liposome is a spherical vesicle whose membrane is composed of a 
phospholipid bilayer, which is used to deliver drugs or genetic materials into 
cells (Figure 27). 
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Fig 27. Schematic reconstruction of a liposome. Different types of liposomes, according to 
their specific use, can be designed. They can be composed of naturally-derived 
phospholipids with mixed lipid chains. 
 
The liposome is a drug carrier system, which is particularly attractive 
when it is composed of natural phospholipids that are well tolerated and have 
minimal toxic side effects. The main objectives of using liposomes as drug 
delivery systems are to increase (formally) the solubility and the stability of 
drugs in vivo, to reduce toxicity, and to achieve drug targeting [84]. The 
association of drugs with liposomes has major effects on their 
pharmacokinetics: liposomes improve drug bioavailability and provide 
targeted drug delivery to the site of action [85]. Thus, liposomal 
formulations have resulted in increased therapeutic efficacy for a variety of 
substances in areas such as cancer [86], antimicrobial [87], and antiparasite 
therapy [88]; [89]; [90]; [91]. 
Prof. Nastruzzi from the University of Ferrara (Italy) prepared 
different compositions of liposomes with and without PPNDS. I tested the 
different liposome preparations adding them to RAW 264.7 cell cultures that 
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were uninfected or infected with mNV, and I analysed the results using the 
MTS assay (see Cell-based assay Materials and Methods paragraph) (Figure 
28). 
 
Fig 28. Antiviral activity (%) vs compound concentrations. PPNDS implies the free PPNDS 
compound; Lip 3 stands for PC 9 mM – DDAB 1 mM – PPNDS 0.1 mM; Lip 4 stays for PC 
9 mM – DDAC 1 mM – PPNDS 0.1 mM  
(PC=phosphatidylcholine;DDAB=Dimethyldioctadecylammoniumbromide;DDAC=Dimeth
yldioctadecylammoniumchloride). 
 
Lip 3, Lip 4 and PPNDS are not toxic (data not shown) on the RAW 
264.7 cell line. However, PPNDS-liposome formulations seem to be not 
active. In contrast, free PPNDS is active with an EC50 of 43.7 µM. Following 
these preliminary results, other experiments are ongoing to further 
characterize the compound’s activity. We hypothesise that PPNDS, as a 
charged molecule (like many sugars) might interfere with virus entry. This 
-40 
0 
40 
80 
120 
0 20 40 60 80 100 %
 A
nt
iv
ira
l A
ct
iv
ity
 
Concentration (µg/ml) 
PPNDS 
Lip 3 
Lip 4 
RdRp targeting antivirals 
 
 100 
could explain why free PPNDS is active. Contrary, PPNDS in liposomes 
cannot interfere with virus entry since it is not release in the medium. 
The antiviral assays described above do not allow to assess whether 
the PPNDS target enzyme is indeed the polymerase domain. In order to 
determine which part of the replication cycle is blocked, a kinetic study 
(Time of Drug Addiction Study) should be performed. 
 
7.2 Antivirals cell-based assays  
In the context of my discovery searches for new antivirals, I tested 
several compounds and drugs from various libraries on different cell-lines 
(RAW 264.7, Vero118 and BHK) infected respectively by mNV, hCoV 
NL63 (human coronavirus) and YFV.  
For each type of virus, I tested the compounds reported in Table 6: 
 
Virus Cell-line Compounds 
mNV CW1 RAW 264.7 
ZC-Tri-G-Mc;  ZC-Tri-G-2OH; ZC-Flex-G-
Mc; ZC-Flex-G-2OH; HP0083; 2’-c-
methylcytidine (2CMC). 
mNV CW3 RAW 264.7 lopinavir; pyrimethamine; nifenazone; 2’-c-methylcytidine (2CMC). 
YFV BHK 
ZC-Tri-G-Mc;  ZC-Tri-G-2OH; ZC-Flex-G-
Mc; ZC-Flex-G-2OH; HP0083; lopinavir; 
pyrimethamine; nifenazone; DZL-0165; DZL-
0983; DZL-0988; DZL-0998; ribavirin; 2’-c-
methylcytidine (2CMC). 
hCoV NL63 Vero118 
ZC-Tri-G-Mc;  ZC-Tri-G-2OH; ZC-Flex-G-
Mc; ZC-Flex-G-2OH; HP0083; lopinavir; 
pyrimethamine; nifenazone; ribavirin; 2’-c-
methylcytidine (2CMC). 
 
Table 6. The compounds tested on each cell lines infected by different viruses 
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ZCs- and HP0083 belong to a NIs library synthesized by a chemistry 
group from University of Maryland (Baltimore, MD, USA), while DZLs- are 
in vitro protease inhibitors, synthesized by a chemistry group from 
University of Lubeck (Lubeck, Germany).  
Lopinavir is an antiretroviral drug belonging the protease inhibitor 
class. It is used against HIV infections as a fixed-dose combination with a 
different protease inhibitor, ritonavir. Lopinavir is highly bound by plasma 
proteins (98–99%). 
Pyrimethamine is a medication used for protozoan infections. It is 
commonly used as an antimalarial drug (for both treatment and prevention of 
malaria), and is also used (combined with the sulfonamide antibiotic 
sulfadiazine) in the treatment of Toxoplasma gondii infections in 
immunocompromised patients, such as HIV-positive individuals. 
Pyrimethamine can increase ß-hexosaminidase activity, thus potentially 
slowing down the progression of Late-Onset Tay–Sachs disease.  
Ribavirin is a guanosine (ribonucleic) analog used to stop viral RNA 
synthesis and viral mRNA capping, thus, it is a NI. It is a pro-drug, which 
when metabolized resembles purine RNA nucleotides. In this form it 
interferes with RNA metabolism required for viral replication. How it 
exactly affects viral replication is unknown; many mechanisms have been 
proposed, but none has been proven to date. Ribavirin is used primarily to 
treat hepatitis C and viral hemorrhagic fevers (which is an orphan indication 
in most countries). Ribavirin is the only known treatment for a variety of 
viral hemorrhagic fevers, including Lassa fever, Crimean-Congo 
hemorrhagic fever, Venezuelan hemorrhagic fever and Hantavirus infection, 
although data regarding these infections are scarce and the drug might be 
effective only in the early stages of the disease. 
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Nifenazone is a drug that has anti-inflammatory, analgesic, 
antipyretic, and platelet-inhibitory actions. Some experiment showed an anti-
helicase activity against DENV. 
2CMC is the first NI of the hepatitis C virus (HCV) NS5B 
polymerase reported. 2'-C-Methylcytidine, as its valyl ester pro-drug 
(NM283), was effective in reducing the viral load in patients infected with 
HCV. 2'-C-methylcytidine is a potent and selective inhibitor of the 
replication of foot-and-mouth disease virus. It is also known to inhibit NV 
RdRp and to have an effect against YFV [92]. In my experiments I have 
used 2CMC as positive control.  
All the information of the above compounds was available through 
the http://pubchem.ncbi.nlm.nih.gov web site. 
All the compounds, with the exception of ZC- and DZ- libraries that I 
cannot display for copyright reasons, are shown in Figure 29. 
 
Fig 29. Chemical structures of compounds tested on mNV, hCoV and YFV. 
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To test the compounds I seeded the cells which adhered to the surface 
of the plate and the day after I added the viruses and different concentrations 
of the compounds. The analysis of the antiviral and cytotoxicity results has 
been done with MTS assay (spectrophotometric assay) for the mNV/RAW 
264.7 cells, while for the other viruses/cell lines the assays were analyzed 
with the Methylene Blue test (see Cell-based assay Materials and Methods 
paragraph).  
2CMC, HP0083 and Lopinavir showed the best inhibition capability 
versus hCoV NL63 with EC50 slightly over 10µM (Figure 30).  
 
 
Fig 30. EC50 and CC50 values of 2CMC, HP0083 and Lopinavir on hCoV NS63 in Vero118 
cells. Green lines refer to cytotoxicity and red lines to antiviral activity of the compounds, 
where 100% means all cells survive. The thin lines are single measures, while the bold lines 
are the averages. The concentration is shown on a logarithmic scale.  
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Lopinavir showed a low CC50 value (high cytotoxicity), therefore I 
focused on the compounds 2CMC and HP0083, quantifying the amount of 
viral RNA present in the cells, previously infected and treated with the two 
compounds, through RT-qPCR (Figure 31) (see Cell-based assay Materials 
and Methods paragraph). The cytotoxicity assay has been analyzed with the 
MTS assay. 
 
Fig 31. RT-qPCR counting the amount of viral RNA in Vero118 treated with 2CMC and 
HP0083 and infected by hCoV. The antiviral activity is expressed as the amount of RNA 
equivalent to the amount of RNA in a virus stock with the indicated titer (expressed in 
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CCID50/Cell; Cell Culture Infectious Dose 50%/Cell) while the cytotoxicity in % of cells 
viability. 
 
 The results confirm that HP0083 is a good inhibitory compound 
since it is not toxic up to 25µg/ml (a compound is considered not toxic if cell 
viability is over 80%). At 25µg/ml it inhibits the hCoV NL63; in fact, 
HP0083 treated cells and CC (cell control) show the same Cell Culture 
Infectious Doses (CCID50). Future experiments have been planned to study 
the inhibition target and the mechanism of action of the selected compound. 
 
8. Materials and Methods 
 
8.1 Cell-based assay Materials and Methods 
8.1.1 Cells and viruses  
mNV (virus strain MNV-1.CW1/CW3) was propagated in RAW 
264.7 cells (Figure 32a) grown in DMEM (Life Technologies) supplemented 
with 10% or 2% FBS, 2 mM L-glutamine, 20 mM HEPES, 0.075 g/L 
sodium bicarbonate, 1 mM sodium pyruvate, 100 U penicillin/mL and 100 
µg/mL streptomycin at 37 °C in a humidified atmosphere of 5% CO2.  
YFV was propagated in Vero118 cells (Figure 32b) grown in IMDM 
(Life Technologies) supplemented with 10% or 1% FBS, 100 U 
penicillin/mL and 100 µg/mL streptomycin at 37 °C in a humidified 
atmosphere of 5% CO2. 
hCoV NL63 was propagated in BHK cells (Figure 32c) grown in 
DMEM (Life Technologies) supplemented with 10% or 2% FBS, 100 U 
penicillin/mL and 100 µg/mL streptomycin at 37 °C in a humidified 
atmosphere of 5% CO2. 
RdRp targeting antivirals 
 
 106 
Fig 32. a) RAW264.7, b) Vero118 and c) BHK cells seeded in well before and after 3 days 
virus infection. Each cell-line is in a different medium.  
 
8.1.2 Antiviral & cytotoxicity: MTS assay 
The antiviral activities of different compounds were determined 
using an MTS [3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-
(4- sulfophenyl)-2H-tetrazolium]-based CPE (Cytopathic effect; damage to 
host cells during virus invasion) reduction assay in the mNV/RAW 264.7 
cell line. To this end, the cells were seeded (2 x 104 cells/well) in 96-well 
plates and infected with mNV at an MOI (Multiplicity of infection; number 
of virions that are added per cell during infection) of 0,001 in the presence 
(or absence) of a dilution series of compounds (0.781–100 µg/ml). 
Following 3/4 days of incubation, i.e. until complete CPE was observed in 
infected untreated cells, an MTS/Phenazine methosulphate (PMS) stock 
solution (2 mg/mL MTS (Promega) and 46 g/mL PMS (Sigma–Aldrich) in 
PBS at pH 6–6.5) was diluted 1/20 in MEM (Life Technologies). To each 
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well, 75 µl of MTS/PMS solution was added and the optical density (OD) 
was read at 498 nm 2 h later. The % CPE reduction was calculated as 
[(ODtreated)mNV - ODVC]/[ODCC - ODVC]*100, where ODCC represents the 
OD of the uninfected untreated cells, whereas ODVC and (ODtreated)mNV 
represent the OD of infected untreated cells and virus-infected cells treated 
with a compound concentration, respectively. The EC50 is defined as the 
compound concentration that protected 50% of cells from virus-induced 
CPE.  
Adverse effects of the molecule on the host cell (cytotoxicity) were 
also assessed by means of the MTS-method, by exposing uninfected cells 
seeded 5 x 103 cells/well to the same concentrations of compounds for 3 
days. The % cell viability was calculated as (ODtreated/ODCC)*100, where 
ODCC is the OD of uninfected untreated cells and ODtreated are uninfected 
cells treated with compound. The CC50 was defined as the compound 
concentration that reduces the number of viable cells by 50%. This MTS 
assay was also performed on Vero118 cell line. 
 
8.1.3 Antiviral & cytotoxicity: Methylene Blue assay  
The cells were seeded (2 x 104 cells/well) in 96-well plates and 
infected with viruses at an MOI of 0,02 for YFV or 0,00001 for hCoV NL63 
in presence (or absence) of a dilution series of compounds (0.781-100 
µg/ml). Following 3/4 days of incubation at 37°C (35°C for hCoV NL63) the 
culture medium in each well was removed. 200 µL Ethanol 70% is added to 
all wells and after one night ethanol is removed. The ethanol addiction 
permit cells fixation. 50 µL of filtered 1 % (w/v) Methylene Blue in PBS 
was added to each well. After 1 h, excess dye was removed. The cell layer, 
still stained with methylene blue, can be examined microscopically. I gave a 
RdRp targeting antivirals 
 
 108 
score to each well depending on the amount of methylene blue fixed (5= 
white, 0= blue) and analyzed the data with an home made program like 
Microsoft Excels.  
The cytotoxicity test was carried out in the same way without 
infected cells.  
 
8.1.4 RNA isolation and quantitative RT-PCR 
The cells in the antivirals plates were seeded 2 x 104 cells/well in 96-
well plates and infected with hCoV NL63 at an MOI of 0.1. After 2h of 
incubation at 35°C, I removed the supernatant, washed the plates with 100µL 
of DMEM 2% FBS and added several concentration of compounds (0.781-
100µg/ml). Following 4 days of incubation at 35°C, the intracellular RNA 
was extracted from cells using the lysis buffer of Ambion® Cells-to-
cDNA™ II Kit (Life Technologies): I removed the supernatant, washed the 
wells with PBS and added 50µl of lysis buffer. After 5 minutes at room 
temperature shaking the plate, I transferred the wells content in a new plate, 
holding it at 75°C for 15 minutes. I analyzed virus control (VC), cell control 
(CC) and two concentration conditions per compound. The qRT-PCR was 
performed in 10µL reaction mixture containing 8µL of SYBR® Green 
reaction mix (BIO RAD) (containing iTaq DNA polymerase, buffers, and 
ROX normalization dyes; iScript™ reverse transcriptase; nuclease-free 
water; primers from nucleocapside protein gene forward 5’-
GTGGAAAACCTTTGGCATCAA-3’ and reverse 3’-
ACCTCGTTGGAAGCGTGTTC-5’) and 2µL of template hCoV RNA. The 
master mix cycling conditions were: reverse transcription at 50 °C for 10 
min, polymerase activation and DNA denaturation at 95 °C for 1 min, 
followed by 40 cycles of denaturation at 95 °C for 15s, annealing and 
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extension at 60 °C for 1 min (Roche lightCycler96w). I analysed the Ct 
(threshold cycle) values with Microsoft office excel. Ct is a relative measure 
of the concentration of viral RNA in the PCR reaction. 
 
8.2 Flavivirus RdRp Materials and Methods 
8.2.1 Expression and purification of the WNV and DENV RdRp 
The WNV RdRp was expressed in Escherichia coli strain C41pLys, 
transformed with plasmid construct pDEST14 in which was cloned ns5 gene 
encoding a N-terminal His6 tag (aa 273-905). Cells were grown at 37°C to 
an OD600 0.6, induced with 0.5mM isopropyl β-D-thiogalactopyranoside 
(IPTG) and further incubated for 16-18 h at 17°C. Cells were harvested by 
centrifugation. The cell pellet was resuspended in TrisHCl 50mM pH 8.00, 
300mM NaCl, 10mM imidazole, 0.8mM DTT, DNase I (2 µg/ml), protease 
inhibitors tablet (Roche), and cells were lysed using a cells disruptor (Basic 
Z Bench top 0.75KW; Constant System). Any insoluble material was 
removed by centrifugation at 4°C and 18000 rpm for 60 min. The 
supernatant was filtered through a 0.44µm filter. The sample was applied to 
a 1-ml bed volume HiTrap nickel immobilized metal ion affinity 
chromatography column (G.E. Ealthcare) connected to a FPLC system (G.E. 
Healthcare). The protein was eluted in a stepwise manner with 50 mM Tris 
buffer, pH 8.0, containing 300 mM NaCl and 260 mM imidazole, 0.8mM 
DTT. Protein-containing fractions were then applied onto a preparative 
Superdex 200 gel filtration column pre-equilibrated in 50 mM Tris buffer, 
pH 9.0, with 300 mM NaCl, 5% glycerol and 1mM DTT. The polypeptide 
composition of the different fraction was monitored by Coomassie-stained 
sodium dodecyl sulfate-polyacrylamide gel electrophoresis analysis. 
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Protein was concentrated to 12 mg/ml using a 10-kDa molecular 
mass cut-off centrifugal concentrator (Millipore), divided into aliquots and 
stored at -80°C. 
DENV-3 RdRp (aa272-900) was cloned into pET15b and expressed 
in BL21pLys. The cell pellet, diluted in a buffer (buffer A) containing 20 
mM Na HEPES at pH 7.0, 300 mM NaCl, 5 mM imidazole and EDTA-free 
complete protease inhibitors (Roche), was lysed using a cells disruptor 
(Basic Z Bench top 0.75KW; Constant System). The lysate was clarified by 
centrifugation at 18000 rpm for 1 h at 4°C. The supernatant was purified by 
1-ml bed volume HiTrap nickel immobilized metal ion affinity 
chromatography column (G.E. Ealthcare) connected to a FPLC system (G.E. 
Ealthcare) by wasching unbound protein with buffer A supplemeted with 40 
mM imidazole. The RdRp was eluted in a stepwise manner with 22.5 mM 
imidazole. For removing the N-terminal His tag, 500 U of thrombin (Sigma) 
was added to the pooled fractions containing the RdRp; the mixture was 
dialyzed overnight against buffer A supplemented with 5 mM TCEP. The 
RdRp was further purified by size exclusion chromatography (Superdex 200) 
using the same buffer. The polypeptide composition of the different fraction 
was monitored by Coomassie-stained sodium dodecyl sulfate-
polyacrylamide gel electrophoresis analysis. Protein was concentrated to 9 
mg/ml using a 10kDa molecular mass cut-off centrifugal concentrator 
(Millipore), divided into aliquots and stored at -80°C. 
 
8.2.2 Flavivirus RdRps inhibition assay.  
RdRp activity was assessed in vitro as described [78]. In brief, we 
followed the synthesis of a double-stranded RNA from a single-stranded 
RNA poly(rC) template (Sigma-Aldrich P4903) annealed with a rG12 primer 
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(62.5 nM final concentration) and 100 µM GTP, in a reaction mixture 
containing 1) for DENV RdRp: 20 mM Tris/HCl (pH 7.5), 1 mM DTT, 25 
mM NaCl, 5 mM MgCl2, 0,3 mM MnCl2, 2 U RiboLock Ribonuclease 
inhibitor (Life technologies), PicoGreen Quantitation Reagent (Life 
technologies) (total volume of 200µl); 2) for WNV RdRp: 50mM Hepes (pH 
8.0), 10mM KCl, 5mM MgCl2, 1mM DTT, 0,5 mM MnCl2, 2 U RiboLock 
Ribonuclease inhibitor (Life technologies), PicoGreen Quantitation Reagent 
(Life technologies) (total volume of 200µl). Before starting the reaction, 1µl 
of the protein (final protein concentration of 620 nM DENV RdRp and 750 
nM WNV RdRp) was added to the mixture together with increasing 
concentrations (from 0 to 30µM) of the inhibitor compounds, previously 
dissolved in 100% DMSO. The reactions were followed for 10 min at 30°C 
measuring PicoGreen fluorescence (Varian, Cary Eclipse Fluorescence 
Spectrophotometer). The protein activity was evaluated subtracting the linear 
slope of the fluorescence from that of the assay mixture in the absence of the 
enzyme. The results of three independent experiments were averaged. 
Measurements of activity vs. inhibitor concentration were used to estimate 
the IC50 of each inhibitor using the program GraFit5 (Erithacus software) 
 
8.2.3 Biophysical characterization of the RdRps/HeE1-2Tyr 
interaction 
The fluorescent dye Sypro Orange (Sigma) was used to monitor 
protein unfolding. The unfolding process exposes hydrophobic regions of the 
protein under investigation, resulting in a fluorescence increase of the dye. 
Thermal shift assays of RdRps in the absence/presence of the inhibitor were 
run in a MiniOpticon Real Time PCR Detection System (Bio-Rad). 
Solutions of 6.4µl and 3.13µl of respectively Dengue and West Nile RdRp 
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domains (final protein concentration Dengue RdRp 26.7µM, West Nile 
RdRp 27.39µM) were mixed with 3.5µl of Sypro Orange diluted 60×, 7.1µl 
of its buffer and 1µl of HeE1-2Tyr (final concentration 8µM). DMSO was 
added in place of the inhibitor for the control samples. The sample plates 
were heated from 20 to 99°C with a heating rate of 0.2°C/min. Fluorescence 
intensities were measured within excitation/emission ranges of 470-505/540-
700nm.  
 
8.2.4 Crystallization of the WNV RdRp and soaking with HeE1-
2SO2/HeE1-2Tyr.  
Microbatch crystallization experiments on WNV RdRp were 
assembled using an Oryx-8 crystallization robot (Douglas Instruments, East 
Garston, UK). In details 0.5 µl drops of 1:1 mixture of protein (12 mg/ml 
initial concentration) and reservoir solution were placed on a 96 well plate 
(Hampton Research), and covered with a mixture of 50% Paraffin oil and 
50% Silicon oil. Prismatic crystals were obtained after 2 weeks at 4°C, in 
300mM MgCl2, 200mM NaCl, 2% Polyethilenglycol 6000, 5% 
Polyethilenglycol 1000, 100 mM TrisHCl pH 7.0. Crystals were soaked in a 
cryoprotectant solution (300mM MgCl2, 400mM NaCl, 6% 
Polyethilenglycol 6000, 5% Polyethilenglycol 1000, 100mM TrisHCl pH 7.0 
and 25% glycerol) with 5mM of HeE1-2SO2 or 15mM of HeE1-2Tyr for 36 
hours, then flash-cooled in liquid nitrogen. Crystals diffracted to a maximum 
resolution of 2.7 Å/4.2 Å respectively, using synchrotron radiation on beam-
line ID29-1 at the European Synchrotron Radiation Facility (ESRF-
Grenoble, France). X-ray diffraction data were processed using MOSFLM 
[93], and intensities were merged using SCALA [94].  
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8.2.5 Structures determination and refinement.  
Both WNV RdRp/HeE1-2SO2 and WNV RdRp/ HeE1-2Tyr crystals 
belong to the space group I222, with unit cell parameters a= 74.57 Å, b= 
104.3 Å, c= 190.87 Å, with 1 molecule in the asymmetric unit. The 3D 
structures were solved by Molecular Replacement (MOLREP program) [95] 
using a search model based on the WNV RdRp structure (PDB: 2HFZ [19]). 
The molecule in the crystal asymmetric unit was subjected to rigid-body 
refinement, and subsequently refined using REFMAC5 [96]. A random set 
comprising 5% of the data was omitted from refinement for R-free 
calculation. Manual rebuilding and additional refinement (with BUSTER 
[97], REFMAC5 and COOT [98]) were subsequently performed, as needed.  
 
 
 
 
 
